Products for Research Use Only

Linaprazan

CAT: 0804-HY-100412-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-100412-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Linaprazan (AZD0865) can inhibit H+, K+ -ATPase in the stomach through K+ competitive binding, (IC50: 1.0 ± 0.2 μM), it has a strong inhibitory effect on acid. Linaprazan (AZD0865) can be used for research on reflux esophagitis with oral activity[1][2][3].
CAS Number
248919-64-4
Product Name Alternative
AZD0865
UNSPSC
12352005
Hazard Statement
H302-H315-H319
Target
Proton Pump
Type
Reference compound
Related Pathways
Membrane Transporter/Ion Channel
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/AZD0865.html
Concentration
10mM
Purity
98.80
Solubility
DMSO : ≥ 35 mg/mL
Smiles
O=C(C1=CN2C(C(NCC3=C(C)C=CC=C3C)=C1)=NC(C)=C2C)NCCO
Molecular Formula
C21H26N4O2
Molecular Weight
366.46
Precautions
P264-P270-P280-P302+P352-P305+P351+P338-P330-P362+P364-P501
References & Citations
[1]Gedda K et al. Mechanism of action of AZD0865, a K+-competitive inhibitor of gastric H+, K+-ATPase. Biochem Pharmacol. 2007 Jan 15;73 (2) :198-205.|[2]Kahrilas PJ et al. A randomized, comparative study of three doses of AZD0865 and esomeprazole for healing of reflux esophagitis. Clin Gastroenterol Hepatol. 2007 Dec;5 (12) :1385-91.|[3]Xinyue Zhang, et al. Absorption, distribution, metabolism and excretion of linaprazan glurate in rats. J Pharm Biomed Anal. 2024 May 15:242:116012.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2